Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Avalon Ventures
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Aug 1, 2024
Deals
Platform, PKU asset drive Otsuka’s $800M takeout of Jnana
As lead program nears pivotal trial, Japanese pharma adds subsidiary to build U.S. discovery capabilities; deal gives strong exit to VC syndicate
BioCentury | Apr 30, 2024
Emerging Company Profile
Enlaza: Creating covalent biologics using engineered amino acids
Avalon-incubated biotech now has $161M to advance what could be the first covalent, irreversible protein drugs, starting in oncology
BioCentury | Mar 25, 2024
Finance
Now a biotech pure-play, Avalon riding ‘sweat equity’ model to outsized returns
A smaller fund size can lead to a higher multiple — especially when a portfolio company such as Janux delivers promising early data
BioCentury | Feb 28, 2024
Product Development
Clinical report: Early efficacy signals triple Janux’s value; Tarsus reveals tick-killing data
Plus: readouts from Sanofi in hives, GSK in gonorrhea; Shionogi’s digital therapeutic and InDex’s next steps
BioCentury | Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Dec 6, 2022
Finance
Avalon creates pure-play biotech VC with new $135M fund
After 11 funds that balanced tech and life sciences, the new Avalon BioVentures will preserve the firm’s sweat equity model
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Aug 19, 2021
Regulation
Aug. 18 Quick Takes: Jardiance’s label gains heart failure indication
RA leads $50M series B for Jnana, plus a deal for Verily, no deal for CureVac and Marinus data
BioCentury | Jun 11, 2021
Product Development
June 11 Quick Takes: First-day bump for Janux; plus Vertex-CRISPR, Curis, Precigen and more
Demand for shares of Janux Therapeutics Inc. (NASDAQ:JANX) was strong enough to lift shares 48% to $25.15 in its first day of trading after the preclinical oncology company priced an upsized number of
Items per page:
1 - 10 of 124